Breast Implant-Associated Anaplastic Large Cell Lymphoma: Two Distinct Clinical Presentations
Keywords:Breast Implants, Breast Neoplasms, Lymphoma, Large-Cell, Anaplastic, Portugal
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare CD30 positive T cell lymphoma whose incidence has recently increased. Until 2020, 733 cases of BIA-ALCL and 36 deaths have been reported around the world, with only one confirmed case in Portugal. The authors describe two clinical cases of BIA-ALCL after breast cancer reconstruction using macrotextured implants. Case 1: A 45-year-old patient, who presented with a typical late-onset seroma five years after breast reconstruction and underwent capsulectomy, confirming localized disease to the capsule. Case 2: A 43-year-old patient presented with an atypical presentation of pleural effusion and tumor mass, 14 years after reconstruction. She underwent implant removal and chemotherapy, due to metastatic disease. These clinical cases illustrate two very distinct clinical presentations of BIA-ALCL. Early diagnosis of this entity allows for effective treatment of the disease, which should be approached in a multidisciplinary setting.
Keech JA Jr, Creech BJ. Anaplastic T-cell lymphoma in proximity to saline-filled breast implant. Plast Reconstr Surg. 1997;100:554-5.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.
Doren EL, Miranda RN, Selber JC, Garvey PB, Liu J, Medeiros LJ, et al. U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2017;139:1042–50.
Food and Drug Administration. Medical device reports of breast implantassociated anaplastic large cell lymphoma. 2020. [cited 2021 Mar 25]. Available from: https://www.fda.gov/medical-devices/breast-implants/medical-device-reports-breast-implant-associated-anaplastic-large-celllymphoma.
Infarmed. Circular Informativa: Informação sobre os implantes mamários e a doença BIA-ALCL. N. º 156/CD/100.20.200. 2020. [cited 2021 Mar 25]. Available from: https://www.infarmed.pt/documents/15786/3464134/Informa%C3%A7%C3%A3o+sobre+os+implantes+mam%C3%A1rios+e+a+doen%C3%A7a+BIA-ALCL/76995a7a-2cfa-998f-5285-08f1f260edba?version=1.0.
Cunha A, Horta R, Barreiro D. Epidemiological profile in Portugal of breast implant associated anaplastic large cell lymphoma: a crosssectional study. Acta Med Port. 2021;34:572-9.
Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014;32:114-20.
Collett DJ, Rakhorst H, Lennox P, Magnusson M, Cooter R, Deva AK. Current risk estimate of breast implant-associated anaplastic large cell lymphoma in textured breast implants. Plast Reconstr Surg. 2019;143:S30-40.
Rastogi P, Riordan E, Moon D, Deva AK. Theories of etiopathogenesis of breast implant-associated anaplastic large-cell lymphoma. Plast Reconstr Surg. 2019;143:23S.
Quesada AE, Medeiros LJ, Clemens MW, Ferrufino-Schmidt MC, Pina-Oviedo S, Miranda RN. Breast implant-associated anaplastic large cell lymphoma: a review. Mod Pathol. 2019;32:166–88.
Jones JL, Hanby AM, Wells C, Calaminici M, Johnson L, Turton P, et al. Breast implant-associated anaplastic large cell lymphoma (BIAALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management. Histopathology. 2019;75:787-96.
Jaffe ES, Ashar BS, Clemens MW, Feldman AL, Gaulard P, Miranda RN, et al. Best practices guideline for the pathologic diagnosis of breast implant–Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2020;38:1102-11.
Clemens, MW, Jacobsen ED, Horwitz SM. NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma. Aesthetic Surg J. 2019;39:S3–13.
National Comprehensive Cancer Network. NCCN Guidelines Version 1.2020. Breast-Implant associated ALCL. Plymouth: NCCN; 2020.
How to Cite
Copyright (c) 2022 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.